Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Acquisitions & Divestments (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Change in Acquisitions & Divestments for 11 consecutive years, with $20.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Acquisitions & Divestments fell 34.43% year-over-year to $20.0 million, compared with a TTM value of $168.0 million through Sep 2025, down 46.75%, and an annual FY2024 reading of $255.5 million, down 7.09% over the prior year.
  • Change in Acquisitions & Divestments was $20.0 million for Q3 2025 at CytomX Therapeutics, down from $32.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $125.0 million in Q4 2023 and bottomed at $10.0 million in Q3 2021.
  • Average Change in Acquisitions & Divestments over 5 years is $61.2 million, with a median of $52.2 million recorded in 2021.
  • The sharpest move saw Change in Acquisitions & Divestments plummeted 81.82% in 2021, then grew 25.0% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $10.0 million in 2021, then surged by 899.8% to $100.0 million in 2022, then increased by 25.0% to $125.0 million in 2023, then plummeted by 48.0% to $65.0 million in 2024, then plummeted by 69.23% to $20.0 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for CTMX at $20.0 million in Q3 2025, $32.5 million in Q2 2025, and $50.5 million in Q1 2025.